Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Some 14% of global prevalence, based on high-income country populations, suffers from migraine. Chronic migraine is very disabling, being characterized by at least 15 headache days per month of which at least 8 days present the features of migraine. Onabotulinumtoxin A, targeting the machinery for e...

Full description

Bibliographic Details
Main Authors: Maria Tiziana Corasaniti, Giacinto Bagetta, Pierluigi Nicotera, Assunta Tarsitano, Paolo Tonin, Giorgio Sandrini, Gary W. Lawrence, Damiana Scuteri
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Toxins
Subjects:
onabotulinumtoxin A
chronic migraine
safety
treatment-related adverse events (TRAEs)
PRISMA 2020
Online Access:https://www.mdpi.com/2072-6651/15/5/332

Internet

https://www.mdpi.com/2072-6651/15/5/332

Similar Items